Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors. These compounds target the ...

Antibodies are pivotal in immunology, driving advancements in precision medicine with monoclonal antibodies, ADCs, and bispecific therapies in cancer research.

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...

Mothers with intrauterine transmission of human cytomegalovirus (CMV) to their newborns despite preconception immunity had higher levels of neutralizing antibodies but had weaker antibody-dependent ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Amivantamab is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, demonstrating efficacy in patients with non–small cell lung cancer ...

SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Cytotoxicity is a broad term that refers to the negative effects of chemical or environmental changes on cell health. Cells exposed to a cytotoxic stimulus may lose metabolic activity, experience ...